Published in
American Society of Hematology, Blood, 4(126), p. 500-503, 2015
DOI: 10.1182/blood-2015-03-631937
Links
- American Society of Hematology | PDF
- ORCID
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4)
Journal article published in 2015 by
Philip Young-Ill Choi 
,
Fernando Roncolato,
Xavier Badoux,
Sundra Ramanathan,
Shir-Jing Ho,
Beng H. Chong
,
Fernando Roncolato,
Xavier Badoux,
Sundra Ramanathan,
Shir-Jing Ho,
Beng H. Chong
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points Triple therapy is well tolerated and effective in patients with chronic ITP. Relapse free survival was 92% for responders after 12 months and 76% after 24 months.